

รายการอ้างอิง

1. เรณู โคตรจรัส. คู่มือโรคผิวหนัง สำหรับแพทย์เวชปฏิบัติทั่วไป. พิมพ์ครั้งที่ 1 กรุงเทพมหานคร : สำนักพิมพ์ห้างหุ้นส่วนจำกัดเอช-เอน การพิมพ์, 2532 : 165.
2. Christophers;E. and Sterry; W. Psoriasis. In T.B. Fitzpatrick , et al (ed.), *Dermatology in general medicine.*, pp. 489-514. New York : McGraw-Hill, 1992.
3. Faber, EM. and Nall, M.L. The Nature history of psoriasis in 5600 patients. *Dermatologica* 1974; 148:118.
4. Halprin, K.M., et al. Cancer patients with psoriasis. *J Am Acad Dermatol* 1982; 7:633.
5. Watson, W. Psoriasis : epidemiology and genetics. *Dermatol Clin* 1984; 2: 363-71.
6. Russell, T.J.; Schultes, L.M, and Kuban, D.J. Histocompatibility (HL-A) antigens associated with psoriasis. *N Engl J Med.* 1972; 287: 738-40.
7. White, S.H; Newcomer, V.D.; Mickey, M.R; and Terasaki, P.I. Disturbances of HLA antigen frequency in psoriasis. *N Engl J Med* 1972; 287: 740-3.
8. Tiilikainen, A, et al. Psoriasis and HLA-Cw6. *Br J Dermatol* 1980; 102: 179-84.
9. Whyte, H.J.; and Baughman, R.D. Acute guttate psoriasis and streptococcal infection. *Arch Dermatol* 1964; 89: 350-6.
10. Abel, E.A., et al. Drugs in exacerbation of psoriasis. *J Am Acad Dermatol* 1986; 15: 1007-22.
11. Heng, M.C.Y.; and Heng, M.K. Beta-adrenoreceptor antagonist induced psoriasiform eruption. Clinical and pathogenetic aspects. *Int J Dermatol* 1988; 27: 619-27.
12. Griffiths, W.A.D.; Ive, F.A.; and Wilkinson, J.D. Topical therapy. In A. Rook, et al (ed), text-book of dermatology, pp 3054-76. Oxford: Blackwell Scientific Publications, 1986.
13. Spark, R.F. Systemic corticosteroids. In T.B. Fitzpatrick, et al (ed.);: *Dermatology in general medicine*, pp. 2859-2864. New York: McGraw-Hill Book Company, 1992.
14. Baker, H. Corticosteroids and pustular psoriasis. *Br J Dermatol* 1976; 94 (Suppl 12): 83-8.
15. Vickers, C.F.H. Topical corticosteroids. In T.B. Fitzpatrick, et al (ed.), *Dermatology in general medicine*, pp. 2849-50. New York: McGraw-Hill Book Company, 1992.

16. Himathongkam, T. et al. Florid Cushing's Syndrome and hirsutism induced by desoximethasone. *JAMA* 1978; 239: 430-1.
17. Munro, D.D. The effect of percutaneously absorbed steroids on hypothalamic-pituitary-adrenal function after intensive use in in-patients. *BR J Dermatol* 1976;94 (Suppl 12) : 67-76.
18. Binderup, L.; and Bramm, E. Effect of a novel vitamin D analog MC 903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. *Biochem Pharmacol* 1988;37:889-95.
19. Kragballe, K.; Beck, H.I.; and Sogaard, H. Improvement of psoriasis by a topical vitamin D₃ analog (MC 903) in a double-blinded study. *Br J Dermatol* 1988;119:223-30
20. Staberg, B.; et al. Efficacy of topical treatment in psoriasis with MC 903, a new vitamin D analog. *Acta Derm Venereol* (Stockh) 1989;69:147-50.
21. Kragballe, K. Treatment of psoriasis by the topical application of the novel cholecalciferol analog calcipotriol (MC 903). *Arch Dermatol* 1989;125:1647-52.
22. Kragballe, K., et al. Double-blinded, right-left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. *Lancet* 1991;337:193-6
23. Cunliffe, W.J., et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. *J AM ACAD DERMATOL* 1992;26:736-43.
24. Morison, W.L., et al. Combined methotrexate-PUVA therapy in treatment of psoriasis. *J Am Acad Dermatol* 1982;6:46-51
25. Stern, R.S., et al. Cutaneous squamous-cell carcinoma in patients treated with PUVA. *N Engl J Med* 1984;310:1156-61.
26. Waldinger, T.P.; Anderson, T.F.; and Voorhees, J.J. Phototherapy. *Dermatol Clin* 1984;2:411-20.
27. Walsdorfer, U.; Christophers, E.; and Schroder, J.M. Methotrexate inhibits polymorphonuclear leukocyte chemotaxis in psoriasis. *Br J Dermatol* 1983;108:451-6.
28. Pye, R.J.; Roberts, S.O.B.; and Champion, R.H. Systemic therapy. In A. Rook, et al (ed.), *Textbook of dermatology*, pp. 2928-43 Oxford:Blackwell Scientific Publications, 1986.

29. Peck, G.L.; and Digiovanna, J.J. Retinoids. In T.B. Fitzpatrick, et al (ed.),*Dermatology in general medicine*, pp. 2883-2908. New York: McGraw-Hill Book Company, 1992.
30. Kojima, T., et al. GRO- alpha mRNA is selectively overexpressed in psoriatic epidermis and is reduced by cyclosporin A in vivo, but not in cultured keratinocytes. *J Invest Dermatol* 1993;101:767-72.
31. Young-HO, W.; Sauder, D.N.; and McKenzie, R.C. Cyclosporin A inhibits keratinocyte gene expression. *Br J Dermatol* 1994;130:312-9.
32. Hansson, Y.; et al. A rapid method for detection of cellular proliferation using carboxyfluorescein: assay of growth factors (IL-2, IL-1) and growth inhibiting antibodies. *J Immunol Methods* 1987;100:261-7.
33. Horrocks, C., et al. Adhesion molecule expression in psoriatic skin lesions and the influence of cyclosporin A. *Clin Exp Immunol* 1991;84:157-62
34. Gottlieb, A.B., et al. Studies of the effect of cyclosporine in psoriasis in vivo:combined effects on activated T lymphocytes and epidermal regenerative maturation. *J Invest Dermatol* 1992;98:302-9.
35. Biren, C.A.; and Barr, R.J. Dermatologic applications of cyclosporine. *Arch Dermatol* 1986;122:1028-32.
36. Van, T.H., et al. Low dose cyclosporin A in severe psoriasis. A double-blind study. *Br J dermatol* 1988;118:183-90.
37. Van, T.H., et al. Short-term use of cyclosporin A in severe psoriasis. *Br J Dermatol* 1986;114:615-20.
38. Farwell, A.P.; and Braverman, L.E. Thyroid and Antithyroid drugs. In J.G. Hardman, L.E. Limbird P.B. Molinoff, R.W. Ruddon (ed.), *The pharmacological basis of therapeutics*, pp. 1397-1400. New York: McGraw-Hill, 1994.
39. Conner, J.M. Thyroid and Antithyroid drugs. In C.R. Graig and R.E. Stitzel (ed.), *Modern Pharmacology*, pp. 781-83. Boston: LiHle, Brown, 1994.
40. Wilson R, et al. The effect of antithyroid drugs on B and T cell activity in vitro. *Clin Endocrinol* 1988;28:389-97.
41. Burman, K.D. Thyroid Hormones. In B. Chernow (ed.), *Pharmacologic approach to the Critically Ill Patient*, pp. 745-46. Baltimore: Williams, Wilkins, 1994.
42. Elias, A.N., et al. Effect of orally administered antithyroid thioureylenes on PCNA and P53 expression in Psoriatic lesions. *Pharmacology and therapeutics*. 1995;34:280-82

43. Greenspan, F.S. and Dong, B.J. Thyroid and Antithyroid drugs. In B.G. Katzung (ed.), *Basic & Clinical Pharmacology*, pp. 587-88. San Francisco: Prentice-Hall International, 1995.
44. Vasily D.B. and Tyler W.B. Propylthiouracil-induced cutaneous vasculitis. *JAMA* 1980;243:458-60.
45. Gammeltoft M. and Kristensen JK. Propylthiouracil-induced cutaneous vasculitis. *Acta Derm Venereol (Stockh)* 1982;62:171-3.
46. Elias, A.N., et al. Propylthiouracil in psoriasis : results of an open trial. *J Am Acad Dermatol* 1993; 29:78-81.
47. Fredriksson T, Pettersson U. Severe psoriasis : Oral therapy with a new retinoid. *Dermatologica* 1978; 157: 238-244.
48. Elias, A.N., et al. A controlled trial of topical propylthiouracil in the treatment of patients with psoriasis. *J Am Acad Dermatol* 1994; 31: 455-58.
49. Elias, A.N., et al. Low dose Oral Propylthiouracil in the treatment of Plaque Psoriasis. *Int J Dermatol* 1995;34:519-20
50. Nickoloff, B.J. Role of gamma interferon in cutaneous trafficking of lymphocytes with emphasis on molecular and cellular adhesion events. *Arch Dermatol* 1988; 124:1835-43.
51. Nickoloff, B.J. Dermal dendrocytes in psoriasis : Autoimmunity forum. *Immunodermatology* 1990; 12:2-4.
52. Barker, J.N.; Allen, M.H.; and MacDonald, D.M. The effect of in vivo interferon-gamma on the distribution of LFA-1 and ICAM-1 in normal human skin. *J Invest Dermatol* 1989; 93:439-42.
53. Duijvestijn, A.M.; Schrieber, A.B.; and Butcher, E.C. Interferon regulates an antigen specific for endothelial cells involved in lymphocyte traffic. *Proc Natl Acad Sci USA* 1986; 83:9114-7.
54. Pober, J.S., et al. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. *J Immunol* 1986; 137:1893-6.
55. Krueger, J.G., et al. Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis . *J Invest Dermatol* 1990; 90(suppl) : 135-405.

56. Nickoloff, B.J., et al. Decreased growth inhibition by recombinant gamma interferon is associated with increased transforming growth factor-alpha production in keratinocytes cultured from psoriatic lesions. *Br J Dermatol* 1989; 121:161-74.
57. Rook, A.H., et al. The immuno pathogenesis of cutaneous T-cell lymphoma. *Arch Dermatol* 1993; 129:486-8.
58. Weetman, A.P., et al. Methimazole and generation of oxygen free radicals by monocytes : potential role in immunosuppression. *BMJ* 1984; 288:518-20.
59. Takagi, S.; Hummel, B.C.W.; and Walfish, P. Thionamides and Arsenite inhibit T₃ binding to hepatic nuclear receptors. *Biochem Cell Biol* 1990; 68:616-21.
60. Baniahmad, A. et al. Modular structure of a chicken lysosome silencer : involvement of an unusual thyroid hormone receptor binding site. *Cell* 1990; 61:505-14.
61. Ronald, Marks., et al. Assessment of disease progress in psoriasis. *Arch Dermatol* 1989; 125:235-240.



ประวัติผู้เขียน

นางไลฟอง โมนา อัครวิชญ์ เกิดวันที่ 21 มีนาคม 2509 ที่ มลรัฐแคลิฟอร์เนีย ประเทศสหรัฐอเมริกา สำเร็จการศึกษาระดับปริญญาตรี แพทยศาสตรบัณฑิต จากคณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย เมื่อปี พ.ศ. 2536 เข้ารับราชการครั้งแรกในตำแหน่งแพทย์ ศูนย์สุขภาพจิตชัชนาท จังหวัดชัชนาท เมื่อวันที่ 1 เมษายน 2536 และได้ลาออกจากราชการ เพื่อศึกษาต่อที่จุฬาลงกรณ์มหาวิทยาลัย ในหลักสูตรวิทยาศาสตรมหาบัณฑิต คณะแพทยศาสตร์ ภาควิชาอายุรศาสตร์ สาขาวิชาตจวิทยา เมื่อวันที่ 1 มิถุนายน 2537